Notice of Results & Investor Presentation

RNS Number : 7321I

Instem plc

20 April 2022

 

Instem plc

("Instem" or the "Company")

Notice of Results

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will announce results for the year ended 31 December 2021 on Tuesday 26 April 2022.

Analyst Presentation: 09.30, Tuesday 26 April

Management will be hosting a presentation via web conference on the day of the results at 09.30. Analysts wishing to join should register their interest by emailing [e-mail]   or by telephoning 020 7933 8780.

Investor Presentation: 16:00, Tuesday 26 April

Management will be providing a presentation and hosting an Investor Q&A session on the results and future prospects at 16:00 on the day, through the digital platform Investor Meet Company. Investors can sign up for free and add to attend the presentation via the following link https://www.investormeetcompany.com/instem-plc/register-investor

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

For further information, please contact:

Instem plc	Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker)	[phone]
Peter Steel Alex Bond Rachel Hayes
Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Ben Maddison
Alex Price
Walbrook Financial PR	[phone]
Tom Cooper	[e-mail]
Nick Rome

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

END

 

 

NORURRWRUSUSURR